NCT05083169 2026-03-18
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT02003222 2025-11-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03319667 2024-11-27
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT04246047 2024-10-24
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting